Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatment of serious diseases with significant unmet medical needs in the orphan drug segment.

Emcitate® (tiratricol)

Our lead product candidate

Pipeline

Corporate presentation

Press Releases

September 3, 2026

Egetis Therapeutics to Participate in Upcoming Investor Conferences in September

Read more

August 31, 2026

Tiratricol Granted Orphan Drug Designation for MCT8 Deficiency in Japan

Read more

Regulatory

August 21, 2026

Egetis’ Interim report Q2 2026

Read more

Upcoming event

September 11, 2026

Cantor Global Healthcare Conference (fireside chat)

Latest presentation

August 21, 2026

Interim report Q2 2026 (webcast)

Latest Report

August 21, 2026

Interim report Q2 2026

Calendar and upcoming reports

September 9-11, 2026

Cantor Global Healthcare Conference

September 14-16, 2026

Morgan Stanley 24th Annual Global Healthcare Conference

November 6, 2026 (7:00am CET)

Interim Report Q3 2026

Joshua’s Story

Share

Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10

E-mail: [email protected]